Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Single Person × Thoracic × Clear all
NCT04767009 2025-04-30

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Fudan University

Phase 2 Unknown
59 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡